CARDIFF ONCOLOGY, INC. Increase (Decrease) in Other Noncurrent Liabilities
CARDIFF ONCOLOGY, INC. (CRDF) reported Increase (Decrease) in Other Noncurrent Liabilities of $0 for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2017-05-10
- CARDIFF ONCOLOGY, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2017-03-31 was $0.00.
- CARDIFF ONCOLOGY, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2016-03-31 was -$268.69K.
- CARDIFF ONCOLOGY, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2015-03-31 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month |
|---|---|
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 |
| 2016-03-31 | -$268.69K 10-Q · filed 2017-05-10 |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |